Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIZE-GNI: Optimization of Beta-lactam Dosing in Critically Ill Patients
NCT06709521Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iohexol in bacterial infection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Clearance, Composite Euclidean distance score and 2 more. Started Feb 2025; status: completed.
02
Drugs
iohexol
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06709521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709521.